<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891068</url>
  </required_header>
  <id_info>
    <org_study_id>2021-0215</org_study_id>
    <nct_id>NCT04891068</nct_id>
  </id_info>
  <brief_title>BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer</brief_title>
  <acronym>BRE-04</acronym>
  <official_title>BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes&#xD;
      (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired&#xD;
      t-tests will be first used to compare TIL count in pre- and post-treatment specimens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes&#xD;
      (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired&#xD;
      t-tests will be first used to compare TIL count in pre- and post-treatment specimens. Median&#xD;
      TIL counts will be compared between the pre- and post-treatment specimens with the Wilcoxon&#xD;
      signed-rank test if TIL count does not follow normal distribution. General linear model (GLM)&#xD;
      or kruskal wallis test will be used in the multivariate analyses to estimate the effect of&#xD;
      low dose azacitidine therapy on TILs after adjusting for other clinical factors and patients&#xD;
      characteristics, including the heterogeneity of tumors.&#xD;
&#xD;
      Screening Evaluation Visit All screening procedures will take place within 30 days of the&#xD;
      first treatment visit unless otherwise noted.&#xD;
&#xD;
        -  Informed consent, HIPAA authorization&#xD;
&#xD;
        -  Medical history including prior and concurrent therapies and pathology&#xD;
&#xD;
        -  Physical exam, height, weight&#xD;
&#xD;
        -  Vital signs (blood pressure, heart rate, temperature)&#xD;
&#xD;
        -  Review of concomitant medications&#xD;
&#xD;
        -  ECOG performance status&#xD;
&#xD;
        -  Blood chemistries (sodium, potassium, serum creatinine [or GFR], calcium, albumin, ALT,&#xD;
           AST, total bilirubin, alkaline phosphatase, total protein)&#xD;
&#xD;
        -  CBC with differential&#xD;
&#xD;
        -  Hepatitis B screening (hepatitis B surface antigen (HBsAg), hepatitis B core antibody&#xD;
           (anti-HBc), total Ig or IgG, and antibody to hepatitis B surface antigen (anti-HBs))&#xD;
&#xD;
        -  Diagnostic Mammogram (NOTE: can be performed up to 60 days prior to study enrollment)&#xD;
           Tumor and axillary assessment&#xD;
&#xD;
        -  Surgical assessment&#xD;
&#xD;
        -  Serum pregnancy test for women of childbearing potential (NOTE: serum βhCG within 14&#xD;
           days prior to study registration).&#xD;
&#xD;
        -  Archival tumor tissue assessment&#xD;
&#xD;
      Azacitidine Treatment Visits Day 1&#xD;
&#xD;
        -  Pre-treated with ondansetron 8mg PO once 30 minutes prior to azacitidine administration.&#xD;
&#xD;
        -  Urine pregnancy test for women of childbearing-potential (NOTE: if &gt;7days since&#xD;
           screening)&#xD;
&#xD;
        -  Research blood draw&#xD;
&#xD;
        -  Azacitidine administration&#xD;
&#xD;
        -  AE assessment&#xD;
&#xD;
      Days 2-5&#xD;
&#xD;
        -  Premedicate with ondansetron 8mg PO once 30 minutes prior to azacitidine administration.&#xD;
&#xD;
             -  Azacitidine administration&#xD;
&#xD;
      Pre study biopsy visit&#xD;
&#xD;
        -  Physical exam, weight&#xD;
&#xD;
        -  Vital signs (blood pressure, heart rate, temperature)&#xD;
&#xD;
        -  Review of concomitant medications&#xD;
&#xD;
        -  ECOG performance status&#xD;
&#xD;
        -  Blood chemistries (sodium, potassium, serum creatinine [or GFR], calcium, albumin, ALT,&#xD;
           AST, total bilirubin, alkaline phosphatase, total protein)&#xD;
&#xD;
        -  CBC with differential&#xD;
&#xD;
        -  Research blood draw&#xD;
&#xD;
        -  AE assessment&#xD;
&#xD;
      Post Study Biopsy Follow-Up visit&#xD;
&#xD;
        -  Physical exam, weight&#xD;
&#xD;
        -  Vital signs (blood pressure, heart rate, temperature)&#xD;
&#xD;
        -  Review of concomitant medications&#xD;
&#xD;
        -  ECOG performance status&#xD;
&#xD;
        -  Research blood draw&#xD;
&#xD;
        -  Archival tumor tissue assessment&#xD;
&#xD;
        -  AE assessment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, window of opportunity trial in which patient with previously untreated high risk early stage breast cancer will receive 5 consecutive days of azacitidine 50mg/m2 SC followed by standard of care therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tumor infiltrating lymphocytes (TILs) count in primary tumors from patients with high-risk early stage breast cancer following low-dose azacitidine therapy.</measure>
    <time_frame>2 weeks from first dose of azacitidine</time_frame>
    <description>Number of participants that show tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response (change Ki67 and tumor size) of primary tumor following treatment with low dose azacitidine therapy</measure>
    <time_frame>2 weeks from first dose of azacitidine</time_frame>
    <description>Number of participants that have a clinical response at time of surgery based on changes in the Ki-67 index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - completion rate of low-dose azacitidine</measure>
    <time_frame>30 days after last dose of azacitidine</time_frame>
    <description>Number of participants that fail to complete the planned course of treatment intervention using the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - tolerability of low-dose azacitidine therapy assessed by using the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5</measure>
    <time_frame>30 days after last dose of azacitidine</time_frame>
    <description>Number of participants that have treatment related adverse events using the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of days participants had DFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of days participants had OS</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Cancer Female</condition>
  <condition>Breast Cancer Invasive</condition>
  <arm_group>
    <arm_group_label>Single arm with previously untreated high risk early stage breast cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive azacitidine 50mg/m2 SC daily for five consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>5-Azacitidine is a pyrimidine nucleoside analog in which nitrogen replaces carbon at position 5</description>
    <arm_group_label>Single arm with previously untreated high risk early stage breast cancer</arm_group_label>
    <other_name>Vidaza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years of age at time of consent&#xD;
&#xD;
          2. ECOG 0, 1, or 2&#xD;
&#xD;
          3. Histologically confirmed invasive breast carcinoma documented by biopsy. AJCC 8th&#xD;
             edition clinical stage T1c-T2/N0-N1/M0 by physical exam or radiologic studies.&#xD;
&#xD;
          4. Primary breast tumor &gt; 1cm&#xD;
&#xD;
          5. Disease characteristics I. TNBC (Less than or equal to 10% of tumor cells staining for&#xD;
             ER and for PR by immunohistochemistry (IHC). HER2-negative, as defined by ASCO/CAP&#xD;
             guidelines)&#xD;
&#xD;
             OR&#xD;
&#xD;
             II. ER positive (as determined by immunohistochemistry (IHC)) and any of the following&#xD;
             high risk characteristics:&#xD;
&#xD;
               1. HER2 positive (IHC or FISH)&#xD;
&#xD;
               2. Node positive&#xD;
&#xD;
               3. Any clinical high-risk expression profile (mammaprint, oncotype, endopredict)&#xD;
&#xD;
               4. PR negative (IHC) OR III. HER 2 positive (as defined by ASCO/ACP guidelines)&#xD;
&#xD;
          6. Demonstrates adequate organ function as defined in table below. All screening labs to&#xD;
             be obtained within 30 days prior to registration.&#xD;
&#xD;
             System Laboratory Value Hematological Leukocytes ≥3,000/mm3 Platelet count ≥&#xD;
             100,000/mm3 Absolute Neutrophil Count (ANC) ≥ 1,500/mm3 Hemoglobin (Hgb) ≥ 9.0 g/dL&#xD;
             Renal Creatinine/Calculated creatinine clearance (CrCl) Cr &lt; 1.5 x upper limit of&#xD;
             normal (ULN) or CrCl ≥ 50 mL/min using the Cockcroft-Gault formula Hepatic Bilirubin&#xD;
             Bilirubin ≤ 1.5 × ULN. Subjects with Gilbert's syndrome may have a bilirubin &gt; 1.5 ×&#xD;
             ULN, if no evidence of biliary obstruction exists Aspartate aminotransferase (AST) ≤&#xD;
             2.5 × ULN Alanine aminotransferase (ALT) ≤ 2.5 × ULN&#xD;
&#xD;
          7. No evidence of distant metastases (M0 per AJCC staging guidelines)&#xD;
&#xD;
          8. Provided written informed consent and HIPAA authorization for release of personal&#xD;
             health information, via an approved UIC Institutional Review Board (IRB) informed&#xD;
             consent form and HIPAA authorization.&#xD;
&#xD;
          9. Women of childbearing potential must not be pregnant or breast-feeding. A negative&#xD;
             serum or urine pregnancy test is required per institutional practice guidelines.&#xD;
&#xD;
         10. As determined at the discretion of the enrolling physician or protocol designee,&#xD;
             ability of the subject to understand and comply with study procedures for the entire&#xD;
             length of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous anti-cancer treatment (cytotoxic chemotherapy, immunotherapy, biologic&#xD;
             therapy, radiotherapy directed towards the primary breast tumor and/or ipsilateral&#xD;
             axillary lymph nodes or investigational agents) with therapeutic intent for the&#xD;
             current breast cancer.&#xD;
&#xD;
          2. Any type of breast implants&#xD;
&#xD;
          3. Active infection requiring systemic therapy&#xD;
&#xD;
          4. Uncontrolled HIV/AIDS or active viral hepatitis&#xD;
&#xD;
          5. Pregnant or nursing&#xD;
&#xD;
          6. Any prior or concurrent malignancy whose natural history or treatment has the&#xD;
             potential to interfere with the safety or efficacy assessment of this investigational&#xD;
             regimen, as determined by the treating medical oncologist.&#xD;
&#xD;
          7. Any mental or medical condition that prevents the patient from giving informed consent&#xD;
             or participating in the trial.&#xD;
&#xD;
          8. Other major comorbidity, as determined by study PI&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vijayakrishna Krishnamurthy Gadi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>VK Gadi, MD, PhD</last_name>
    <phone>312-996-1581</phone>
    <email>vkgadi@uic.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerry Day, BA</last_name>
    <phone>312-413-1069</phone>
    <email>kbartl1@uic.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Illinois Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>VK Gadi, MD</last_name>
      <phone>312-996-1581</phone>
      <email>vkgadi@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kerry Day, BA</last_name>
      <phone>312-413-1069</phone>
      <email>kbartl1@uic.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Illinois Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VK Gadi, MD</last_name>
      <phone>312-996-1581</phone>
      <email>vkgadi@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kerry Day, BA</last_name>
      <phone>3120413-1069</phone>
      <email>kbartl1@uic.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 11, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>August 28, 2021</last_update_submitted>
  <last_update_submitted_qc>August 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Vijayakrishna Krishnamurthy Gadi</investigator_full_name>
    <investigator_title>Prinicpal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

